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Background. P-gp expression has been linked to the efflux of chemotherapeutic drugs in human cancers leading to multidrug
resistance. Fluorescence techniques have been widely applied to measure the P-gp activity. In this paper, there is a comparison
between the advantages of two fluorescence approaches of commonly available and affordable instruments: the microplate reader
(MPR) and the flow cytometer to detect the P-gp efflux activity using calcein-AM. Results. The selectivity, sensibility, and
reproducibility of the two methods have been defined. Our results showed that the MPR is more powerful for the detection of
small inhibition, whereas the flow cytometry method is more reliable at higher concentrations of the inhibitors. We showed that to
determine precisely the inhibition efficacy the flow cytometry is better; hence, to get the correct Emax and EC50 values, we cannot
only rely on the MPR. Conclusion. Both techniques can potentially be used extensively in the pharmaceutical industry for high-
throughput drug screening and in biology laboratories for academic research, monitoring the P-gp efflux in specific assays.
1. Background
Development of chemoresistance by cancer cells is a major
burden in cancer treatment. Tumor resistance to specific
treatment could result from (i) interaction with the host
[1] or (ii) genetic or epigenetic alterations of malignant
cells [2]. Resistance may be innated or acquired during
treatment. In some patients, prolonged exposure to a single
agent may lead to resistance to multiple other structurally
unrelated antineoplasic drugs, a phenotype early defined as
Multidrug Resistance (MDR) [3]. MDR has been closely
related to overexpression of a membrane-associated 170-kD
transmembrane glycoprotein, P-glycoprotein (P-gp), which
appears to play a key role in drug efflux [4, 5]. P-gp is a
member of a highly conserved superfamily of ATP-binding
cassette (ABC) transport proteins that actively pump out
of the cell many potentially endogenous and exogenous
toxic compounds [6–8], collectively called P-gp allocrites [9].
P-glycoprotein is therefore considered as a biomarker for
drug resistance [10]. Detection of P-gp-positive cells within
tumors have been carried out by various techniques [11]
such as determination of ABCB1 transcript levels by RT-
PCR [12] and protein expression by immunocytochemistry
[13]. However, a better correlation between cell resistance
factor and presence of P-gp was obtained in functional assays
where cell efflux capability is quantified by using a P-gp
fluorescent allocrite [14, 15]. Direct measurement of P-gp
activity offers a better level of functional integration, taking
into account posttranscriptional and extragenetic regulations
of efflux-based resistance to cytotoxics [16]. It then becomes
mandatory to accurately evaluate P-gp activity in order to
assess its role in the occurrence of chemoresistance.
Calcein acetoxymethyl ester (calcein-AM) is a nonfluo-
rescent, highly lipid soluble dye that passively crosses plasma
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membranes. Calcein-AM is widely used to quantify MDR
efflux activity, as this molecule behaves as an allocrite for sev-
eral ABC transporters, namely, ABCB/P-gp and ABCC/MRP
(Multidrug Related Protein) pumps [17, 18]. Once inside
the cell, ester bonds are cleaved by endogenous esterase,
transforming calcein-AM into a hydrophilic and intensely
fluorescent calcein, which is well retained in the cytosol.
MDR cells expressing high levels of P-gp rapidly extrude
nonfluorescent calcein-AM from the plasma membrane,
reducing accumulation of fluorescent calcein in the cytosol.
As a result, fluorescence intensity is inversely related to P-gp
activity.
The calcein fluorescence level can be measured by a
fluorometer, often a microplate reader (MPR), assessing the
fluorescence as a whole (cultures isolated from biological
samples) [19] or cell by cell using a flow cytometer [20].
However, influence of the measuring approach onto the
deduced mean cell fluorescence or onto the reconstituted
cell fluorescence distribution in the analyzed population
is often not considered. Herein, we have compared well-
fluorescence and cell-fluorescence methods in drug-resistant
human MCF-7 and Hs578T cell lines in order to understand
better how variations of cell fluorescence intensity can affect
the signals given by the instruments.
2. Results
The P-glycoprotein activity was assessed by using fluorigenic
dye calcein-AM, as a substrate for efflux of P-gp. As a
result, calcein fluorescence is inversely proportional to P-
gp activity. Two methods (flow cytometry and microplate
reader) have been optimized to measure the effect of a
competitive (VRP) and a noncompetitive (PSC833) P-gp
inhibitor on the calcein accumulation in two parental breast
cancer cells lines, and their resistant variants MCF-7/Doxo
(Figure 1(a)) and Hs578T/Doxo (Figure 1(b)). In this study
we compared these two approaches in order to assess their
sensitivity and specificity for P-gp detection in accumulation
and retention assays. Ten experiments have been performed
for each condition. One experiment consists in 6 replicates in
microplate reader and a sample of 10,000 cells using a flow
cytometer.
2.1. Quantifications of the Calcein AM Fluorescence in a
Single Well Microplate Reader versus Single Cell. First, we
determined with microplate reader the effect of VRP and
PSC833 P-gp inhibitor on the intracellular trapping of calcein
(Figure 1). Then, we adapted the microplate reader method
with few modifications to increase its sensitivity. This gives
us a global fluorescence of the well without taking into
account the cell number. To overcome this issue, we decided
to carry out MTT assays, to take into consideration the
heterogeneity in the cell number distributionwhile setting up
the experiment. We generated an OD/MTT scale by reading
a known number of cells after MTT (𝑛 = 6). We generated
an MTT calibration curve for each cell line which can fit
by a classical enzymatic curve (MCF-7/Doxo 𝑟2 = 0.9773;
Hs578T/Doxo 𝑟2 = 0.9840). MTT OD was between 0.2 and
0.8, consequently in the linear part of the curve, allowing us
to determine the cell number. It is interesting to note that the
cells number gave an ODmax/2 at a value of 175000 cells/well
for MCF-7 compared to 115000 cells/well for Hs578T. This
suggests that for comparing both cell lines, it is important
to take into account an activity/number of cells and not an
activity/OD MTT. Therefore, the single cell fluorescence was
obtained after normalization with the cell number in each
well. Applying this method of analysis, we have been able
to express microplate reader calcein fluorescence in single
cell fluorescence. Interestingly, it has been observed that the
PSC833 is more effective than the VRP.
2.2. Flow Cytometry Cell Population Fluorescence (FL1) versus
Fluorescence Concentration (FL1-FC). By using a Beckman
Coulter cell lab quanta with electronic volume instead of
forward scatter (Figure 2), we were able to take into account
the cell volume in fluorescence analysis. This normalization
is important as the cell volume is changing among the
same population. Therefore, we determined both the specific
cell fluorescence concentration (FL1-FC) and the classic
fluorescence (FL1). The results are reported in Figure 2.
Then we measured the effect of the two P-gp blockers. No
significant differences between analyses on FL1 or FL1-FC
have been found. For further experiments, we choose to read
our sample in FL1-FC. Indeed, the specific cell fluorescence
concentration can potentially be used with primary cultures
that are known to be very heterogeneous. We confirmed by
this method that the PSC833 is more effective than the VRP.
2.3. Limit of Detection (LOD). We wanted to determine the
LODof bothmethods used tomonitor the P-gp efflux activity
under treatment. The LOD of an analytical method is an
important parameter when quantitative measurements have
been done. In quantum chemistry, LOD is defined as the
smallest concentration of a substance that could be detected
but not quantified. The LOD of our methods correspond to
the smallest efflux activity variation measurable between two
P-gp inhibitors. Therefore, we choose a low concentration
of inhibitors 100 nM of PSC833 or VRP. The intermethods
comparison indicates that for the less powerful blocker, VRP,
the LODwas enhanced using themicroplate reader.However,
for the most powerful, PSC833, the LOD is similar using
both techniques. For theMPR, the intramethod comparisons
compare the mean fluorescence versus the normalize fluores-
cence; and for the flow cytometry, to compare FL1 to FL1-FC.
In both cases, LODs were not enhanced with the different
data processing. A summary of our results is shown in
Table 1.
2.4. Linearity. Linearity defines the analytical response as
a function of analyte concentration over which acceptable
linearity is achieved.Therefore,MCF-7 parental sensitive cells
were incubated with different concentrations of calcein-AM
(Figure 3). Linear regression has been used to fit each con-
centration (microplate reader 𝑟2 = 0, 9929; flow cytometry
𝑟
2
= 0, 9951). Measured values were proportional to calcein
concentration used. Hence, we can conclude that linearity
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Figure 1: Effects of P-glycoprotein blockers on calcein-AM efflux obtained by quantifying whole well or cell-normalized well fluorescence
with a microplate reader. P-gp activity was measured as the ability to efflux the fluorescent P-gp allocrite calcein-AM. MCF-7/Doxo (a) or
Hs578T/Doxo (b) multidrug resistant P-gp overexpressing breast cancer cell lines were incubated with 0, 1, or 10𝜇M of the P-gp antagonists
verapamil (VRP) or PSC833. Left: global cell population P-gp activity was quantified by measuring whole well fluorescence (arbitrary units,
A.U.) in 6-plicates for 10 repeated experiments in each condition. Middle: a normalized single cell P-gp activity (A.U.) was obtained from
cell population in each well by computing the ratio of whole well fluorescence to the number of cells in the corresponding well. In this
respect, an MTT assay was systematically performed after the fluorescence readings to determine the number of cells in each well of the
microplate. Right: MTT calibration curves. MTT optical density (MTTOD) varied as a function of the number of cells (NC) deposited in the
wells, in a saturation type Mickaelis-Menten relationship. For calibration, the number of cells was determined by using a Malassez counting
chamber. Curve fitting to the data gave the following parameters: 𝑎 = 5, 27; 𝑏 = 175092 for MCF-7/Doxo cells and 𝑎 = 7, 64; 𝑏 = 113025
for Hs578T/Doxo cells, respectively. Data are presented as mean ± sem with 𝑛 = 10 independent assays per data point. Results significantly
different from the control are indicated (∗𝑃 < 0, 05; ∗∗𝑃 < 0, 01; ∗∗∗𝑃 < 0, 001; paired Student’s 𝑡-test).
is acceptable up to 1 𝜇M. For monitoring P-gp efflux, we
used a concentration of 0.25𝜇M; the linearity was therefore
adequate for both methods.
2.5. Precision. The precision (also called reproducibility or
repeatability) is the degree to which repeated measurements
are able to show the same results under unchanged condi-
tions.Thus, precision quantifies the variability of an analytical
result as a function of operator, method manipulations, and
day-to-day environment. Statistical analysis of data generated
are essential to demonstrate assay precision.
Repeatability, in flow cytometry, consists to analyse the
peak distribution in only one experimentation. The coeffi-
cient of variation (CV) obtained from the 10 experiments
with each blocker has been determined using the cell lab
quanta software (Figure 4(a)). In the control conditions
(concentration = 0), the CV values are scattered. This means
that the efflux capacity of the P-gp is heterogeneous in
resistant cell population. It has been observed that CV values
decrease as VRP or PSC833 concentration increases. All the
cells converge to a nonactivity response corresponding to the
concentration maximal for the calcein in the cells. Moreover,
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Figure 2: Effects of P-glycoprotein blockers on calcein-AM efflux obtained by analyzing single cell fluorescence (FL1) or fluorescence
concentration (FL1-FC) with a flow cytometer. P-gp activity was followed with calcein-AM as a fluorescent probe. In each flow cytometry
measurement, a sample of 10 000 cells was analyzed. (a) Top panels, left: superimposed all-events histograms of calcein fluorescence
distribution (log scale) in control MCF-7/Doxo (solid gray histogram) and MCF-7/Doxo preincubated with the P-gp noncompetitive
antagonist PSC-833 (10𝜇M, open histogram). Right: the amount of fluorescence per cell is expressed as FL1-FC (fluorescent light in channel
1-fluorescence concentration) which is the fluorescent light (FL) divided by the electronic volume (EV) determined by the flow cytometer
according to the Coulter Principle. The EV distribution of the sample is given in insert. Bottom panels: the two histograms present the mean
fluorescence, FL1 (left) and the cell volume normalized fluorescence, FL1-FC (right) without or with 1 𝜇M or 10𝜇M of PSC833 or verapamil
(VRP) for 10 repeated experiments. (b) The same experiments were carried out in Hs578T/Doxo. Data are presented as mean ± sem with
𝑛 = 10 independent assays per data point. ∗𝑃 < 0, 05, ∗∗𝑃 < 0,01, ∗∗∗𝑃 < 0, 001.
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Figure 3: Microplate reader and flow cytometer fluorescence responses linearity. MCF-7 drug-sensitive parental cells were incubated during
15minutes in the darkwith 0,05; 0,1; 0,25; 0,5; 0,75, or 1 𝜇Mof calcein-AM.Cells were analysed by flow cytometry formean volume-normalized
fluorescence (FL1-FC, (a)) and by amicroplate reader for cell-normalized well fluorescence (b). Data are presented as mean ± semwith 𝑛 = 10
independent assays per data point.
Table 1: Intermethods comparison of fluorescence increase detec-
tion thresholds.
MCF-7 Hs578T
0,1 𝜇M
VRP
0,1 𝜇M
PSC833
0,1 𝜇M
VRP
0,1 𝜇M
PSC833
Flow cytometer
Mean FL1 ∗∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Mean FL1-FC ∗∗ ∗ ∗ ∗ ∗ ∗∗
Microplate reader
Well fluorescence ∗ ∗ ∗ ∗ ∗∗ ∗∗
Single cell
fluorescence ∗ ∗ ∗ ∗ ∗ ∗ ∗∗ ∗∗
Flow cytometer (mean FL1 and mean FL1-FC) and microplate reader
(whole well fluorescence and mean single cell fluorescence) signal increase
detection thresholds were estimated by testing groups of untreated cells and
cells treated with the lowest P-gp antagonists concentration (0,1𝜇M) for
significant differences (∗P < 0,05; ∗∗P < 0,01; ∗∗∗P < 0,001; paired Student’s
t-test; 𝑛 = 10).
the CV values distribution becomes more clustered when
the blocker concentration increases. In conclusion, there is a
better repeatability with higher P-gp blocker concentrations.
Using the microplate reader, repeatability corresponds to
the CV values of 6 replicates carried out for each experiment
(Figure 4(b)). With the flow cytometry, we read directly CV
values from the software but with the microplate reader,
CV values were calculated using the following mathematical
equation: CV = 100 × standard deviation/mean, with 6
replicates of each of 10 experiments. There was no difference
in the CV values between blockers concentration. Then, we
can conclude, the repeatability is independent of the blocker
concentrations in the microplate reader.
Replicability is the variability of the measurements
obtained by one person while measuring the same item
repeatedly. To underline the compared repeatability between
both methods, the mean fluorescence (FL1-FC) was formu-
lated as function of single cell fluorescence for each PSC833
concentration for the 10 biological replicates (Figure 5).
Thus, each point represents a separate experiment within
same manipulation condition on MCF-7/Doxo. Each graph
represents a PSC833 concentration. For high concentration
of PSC833, sample values diverge away from the ratio of the
means for the two methods. In conclusion, when blockers
are used in high concentration, the single cell fluorescence is
more variable.
2.6. Difference between the Two Methods. To compare both
measuring techniques, we formulated the differences by using
Altman and Bland method [21]. Fluorescence was expressed
as a function of control (FLblock/FLctrl = Δ𝐹). Mean of flow
cytometry fluorescence or MPR fluorescence were shown on
the 𝑥 axis and the difference on the 𝑦 axis (Figure 6). When
the blockers concentration was increased, the difference
between the two methods was higher. This result means
that the difference between the highest fluorescence and the
lowest fluorescence ismore important in flow cytometry than
in the MPR.
2.7. Doses Responses Curves. Doses responses curves repre-
sented in Figure 7 allowed us to determine the EC
50
(half
maximal effective concentration) of each blocker for each
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Figure 4: Intramethod technical replicability within ten independent biological samples. (a) Graphs show coefficient of variation (CV) of
ten independent samples analyzed by flow cytometry after treatment with various concentrations of VRP (left) or PSC833 (right). A sample
consists in the analysis of 10 000 cells. CV is expressed as the ratio of the standard deviation (SD) of the peak to the mean channel value
(in percent) and provides a measure of the variability in signal intensity. (b) Coefficient of variation (CV = 100 × SD/mean) of 6-plicated
measurements of fluorescence obtained with a microplate reader for ten independent biological samples exposed to different concentrations
of VRP.
method. The experimental point was fitted with doses-
responses curves by Sigma Plot 11 Software. EC
50
and 𝐸max
(maximal effect) were reported in Table 2. Although, the
potency of PSC833 in all cell lines tested was similar with
the two methods, results with VRP were highly fluctuating.
Based on the differences seenwhen the blocker concentration
increases, we conclude that efficacy level obtained with flow
cytometry was higher than that of the microplate reader
method.
Therefore, analysing themean fluorescence of the popula-
tion resulted in a loss of information using the technique flow
cytometry. Indeed, for the low level of fluorescence, the signal
varies from 1 to 10, whereas for the higher one, the signal
oscillated between 10 and 5000 (Figure 2). This indicates that
at the time of measurement, the inhibitors did not have the
same efficacy on the different cell subpopulations. Therefore,
when using the inhibitors, the fluorescence mean values
were different from the most often detected fluorescence
(fluorescence at the peak or mode). Thus, we represented
Table 2: EC
50
and 𝐸max values obtained from the doses responses
curves.
EC
50
(𝜇M) 𝐸max
FC MPR FC MPR
MCF-7/Doxo
PSC833 1,40 1,23 16,03 6,01
MCF-7/Doxo
VRP 28,29 68,04 24,59 10,39
Hs578T/Doxo
PSC833 1,83 1,40 11,99 4,48
Hs578T/Doxo
VRP 102,00 24,96 44,70 6,27
Values are given for the two methods (flow cytometry—FC and microplate
reader—MPR)with the twodifferent antagonists for the two cells lines,MCF-
7/Doxo and Hs578T.
the doses responses curves with the fluorescence at the
peak for the PSC833 in flow cytometry (Figure 8). This data
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Figure 5: Intermethods comparison of repeatability for increasing PSC833 concentration. Each graph shows the distribution of calcein
fluorescence in 10 samples analyzed with both methods. Cell-normalized well fluorescence in microplate reader is expressed as a function of
cell fluorescence concentration (FL1-FC) in flow cytometry for increasing concentrations of PSC833. Straight line corresponds to the mean
methods fluorescence ratio.
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Figure 6: Method responses differential as a function of mean fluorescence.The graph shows the differences between fluorescence measured
in flow cytometry (FL1-FC) and microplate reader (cell-normalized well fluorescence) as function of mean fluorescence measured in these
two methods. Gap between flow cytometry and microplate reader responses linearly increased with P-gp blockers-induced fluorescence
accumulation.
representation is impossible for the VRP because this
inhibitor was not effective enough. EC
50
calculated with this
representation seem to fit with the data obtained for the
mean of fluorescence, while the 𝐸max values were completely
different.
3. Discussion and Conclusion
In this paper, we compared simple, sensitive, and specific
methods with fluorescence detection for the P-gp efflux
activity in MCF-7 and H5578T, as well as in resistant variants
of these cell lines, MCF-7/Doxo and H5578T/Doxo. Regard-
less of the technical issues, both described methods, flow
cytometry and microplate reader can be used to measure the
in vitro effectiveness of P-gp inhibitors at low concentrations.
First, we studied the effects of P-glycoprotein blockers on
calcein-AM efflux by quantifying the empire fluorescence
of the whole well or cell-normalized well fluorescence with
a microplate reader. There were no important differences
between the two different ways of analysis, however, we
should emphasize that we used two MDR cell lines that
are really homogenous. The same experiments should be
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Figure 7: Intermethods comparison of PSC833 and verapamil doses responses curves expressed as mean fluorescence. Superimposed
microplate reader and flow cytometry semilogarithmic doses responses curves showing the effect of increasing verapamil or PSC833
concentrations on calcein accumulation inMCF-7/Doxo (a) orHs578T (b). Each point representsmeans± sem (10 independent experiments)
of cell-normalized well fluorescence (open circles) or flow cytometry mean FL1-FC (filled circles) expressed as the ratio of signals in the
presence of blocker to signals in control conditions. Ligand binding sigmoidal doses responses curves were fitted to the data to obtain blockers
potencies (half-maximal effective concentration, EC
50
) and efficacies (maximum response, 𝐸max).
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Figure 8: Flow cytometry PSC833 doses responses curves obtained by analyzing modal single cell fluorescence concentration (FL1-FC).
Semilogarithmic doses responses curves showing the effect of increasing PSC833 concentrations on calcein accumulation in MCF-7/Doxo.
Each point represents peak (modal) ± sem (10 independent experiments) of FL1-FC in MCF7/Doxo (a) or Hs578T/Doxo (b) expressed as the
ratio of signal in the presence of PSC833 to signal in control conditions. Ligand binding sigmoidal doses responses curves were fitted to the
data to obtain PSC833 potency (half-maximal effective concentration, EC
50
) and efficacy (maximum response, 𝐸max).
performed using coculture or primary cells. This conclusion
is the same for the analysis with FL1 and FL1-FC in flow
cytometry. When we compare the results obtained with flow
cytometry or MPR, we can see that the differences between
basal fluorescence and fluorescence in presence of blockers
are nearly the same between the two methods. Both methods
have the same range of scale to detect P-gp activities. And this
is confirmed by the LOD analysis.
The intramethod comparisons showed that when we
analysed the fluorescence by flow cytometry the CV value
is inversely correlated with the fluorescence level, which
correlates to the efflux activity. Therefore, the flow cytometer
is more accurate for higher level of inhibition. When we
analysed the fluorescence by MPR, the CV values seem to be
independent of the efflux activity. We could therefore discern
a “V” pattern using the MPR CV values, with the smaller CV
values reflecting intermediate efflux activity.
The two methods indicate with precision the blocker
answers disparity. Thereby, when we express the single cell
fluorescence in MPR as a function of the mean FL1-FC, we
can notice that when the fluorescence increases, the values
are dispersing around the diagonal but remain around the
medium ratio values.
When we compared the two techniques by using the
Altman and Bland method, we noticed that when the fluo-
rescence increases the difference between the two methods
was amplified. The fluorescence variance increases linearly
with the fluorescence level which suggests that the efficacy
of the MPR decreases with the increasing of P-gp inhibition.
Thus, we were not able to determine an accurate value for
𝐸max with the MPR method. There is also a consequence
on the EC
50
determination. For the more effective inhibitor
(PSC833), EC
50
is the same with the two methods. However,
for the less effective inhibitor (VRP), the curve never reaches
saturation and as a result of that, the accurate 𝐸max cannot
be determined by the MPR technique. Using flow cytometry,
PSC833 doses responses curves obtained by analysing modal
single cell fluorescence concentration (FL1-FC) confirmed
the EC
50
values obtained with the classical dose response
curve. Therefore, the 𝐸max values are higher because no
detection of the fluorescence dilution was detected from the
cells which are less affected by the inhibitor.
In conclusion, the MPR is more powerful for the detec-
tion of small inhibition but the flow cytometry method is
more reliable at higher concentrations of inhibitors. This
observation is the same for both inhibitors tested. Therefore,
it is independent of the sort of the blocker. To determine
precisely the inhibition efficacy it is important to use the flow
cytometer. To give correct value for𝐸max and EC50, we cannot
rely on the MPR method.
Therefore, microplate reader could be used to screen P-
gp blockers and flow cytometry for accurate analysis. In
summary, the presented methods are simple and can be
routinely used in determination of potential P-gp inhibition
of various compounds. Depending on the user’s specific
needs, both methods can be applicable and potentially used
to detect effects of competitive and noncompetitive P-gp
blockers.
4. Methods
4.1. Cell Lines. The study was carried out with human breast
carcinoma derived cells, MCF-7 and Hs578T and multidrug
resistant variant of these cells lines (MCF-7/DOXO and
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Hs578T/DOXO), kindly obtained from Pr. J. P. Marie (Hoˆtel
Dieu, Paris, France). MCF7/DOXO and Hs578T/DOXO
cells were, respectively, isolated by stepwise selection with
increasing concentrations of doxorubicin [22]. Cells were
maintained in RPMI 1640 (Sigma, St. Louis, MO) containing
5% heat-inactivated fetal bovine serum (Sigma, St. Louis,
MO), 2mM L-glutamine (Sigma, St. Louis, MO), and 1%
antibiotic/antimycotic solution (Sigma, St. Louis, MO) and
incubated in a humidified atmosphere containing 5% of CO
2
at 37∘C.
4.2. Reagents. Purified doxorubicin (DOXO), verapamil
(VRP), DMSO, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide), and phosphate buffer saline
(PBS buffer, pH 7.4) were purchased from Sigma (St. Louis,
MO). Calcein acetoxy-methylester (calce´ine-AM) was
supplied by Invitrogen Life Technologies (Carlsbad, CA).
SDZ PSC833 (PSC833) was kindly provided by Pr. J. P. Marie
(Hoˆtel Dieu, Paris, France). Final concentration of DMSO
and H20 was less than 0.1%.
4.3. Samples Preparation. For the calcein-AM efflux assay,
cells were cultured at 80 or 90% confluency in T25. Cells were
detached by trypsin/EDTA treatment. The experiments were
initiated by washing the cells with PBS. Cells were treated
with 0, 1, or 10𝜇M of antagonists VRP or PSC833 at 37∘C for
30min.Then 0,25 𝜇Mof calcein-AMwere added to eachwell.
After 15min incubation at 37∘C, cells were washed twice with
PBS and splitted to quantify P-gp activity by fluorescence in
a microplate reader or in a flow cytometer. Ten experiments
were independently performed for each condition.
4.4. Measurement of P-gp Activity. For the evaluation activity
by flow cytometry, fluorescent light (FL) was quantified using
a cell lab quanta SC MPL flow cytometer (Beckman Coulter)
equipped with a 22mW 488 nm excitation laser. The voltage
settings of photomultipliers remained unchanged throughout
the experiments. For each analysis we recorded 10,000 events,
triggered on electronic volume (EV) as primary parameter,
according to a particle diameter exceeding 8 𝜇m. Green FL of
calcein was quantified via the FL1 channel (log scale) through
a 525 nm band pass filter.
For the evaluation of P-gp activity by microplate
reader, calcein fluorescence was quantified using a FL-600
microplate fluorometer (Bio-tek instruments,Winooski, VE).
For each experiment, six wells were measured in parallel
(𝑘ex = 494 nm and 𝑘em = 517 nm).
4.5. Cell Viability Study (MTT Assay). In order to take the
number and viability of cells into account, an MTT assay was
systematically performed after reading the calcein fluores-
cence. 10% of MTT reagent was added to each well to a final
concentration of 500𝜇g/mL, and the cells were incubated
for 4 hours at 37∘C. The medium has been then replaced
with 200𝜇L of DMSO to dissolve the reaction product. The
optical density was read at 570 nm versus 630 with an Elx
808 microplate reader (Bio-tek Instruments, Winooski, VE).
Normalized calcein accumulation was then expressed as the
ratio of the well fluorescence to the MTT absorbance.
4.6. Statistics. For statistical analysis and graphical rep-
resentation, Excel (Microsoft Corporation) and SigmaPlot
(SysStat, Erkrath, Germany) softwares were used. Numerical
results are given as means ± SEM (𝑛 = sample size). The
statistical significance was assessed with SigmaPlot or Excel
software according to either a Student’s 𝑡-test. Statistical
significance was accepted for ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 <
0.001.
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